For instance, it has been demonstrated that a significant percentage of patients with KRAS/NRAS wild-type CRC undergoing treatment with EGFR inhibitors will develop RAS mutations at the time of progression [4]. This evidence concerns the gene KRAS and colorectal carcinoma.